J&J vaccine needs study

Blood clots in veins that drain blood from the brain can lead to alarming strokelike results. The symptoms can be severe headaches, abdominal pain, leg pain and shortness of breath.

That’s why it made sense for federal, state and local health officials to hit pause Tuesday and again on Wednesday on continued distribution of the Johnson & Johnson COVID-19 vaccine. Six known cases of a rare clotting disorder called cerebral venous sinus thrombosis in women between the ages of 18 and 48 might be linked to the vaccine. More information is needed.

On Wednesday, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention met to decide next steps. The committee opted for additional time to gather information. They also learned more about the six women, one of whom died 11 or 12 days after receiving the vaccine — a 45-year-old woman with no known risk factors — and other reactions that could be linked to the vaccine.

A Nebraska woman, 48 years old, presented with possible cerebral venous symptoms 14 days after the vaccination. She has not recovered. The youngest woman with possible serious side effects, an 18-year-old from Nevada, experienced complications, including cerebral venous sinus thrombosis, 14 days after vaccination. Her status, doctors said, is “not recovered.”

Five of the six women reported headaches initially. Later, some of them reported left-side weakness, vomiting, vision troubles, severe abdominal pain and loss of consciousness. Three remain hospitalized with two in intensive care, doctors said on Wednesday.

The individual stories are scary to be sure.

But it’s critical to keep them in context. Of the nearly 7 million doses given across the U.S., only six suspected cases with this side effect are known so far.

The vaccine remains effective in inoculating patients from COVID-19 66 percent of the time and limiting severe cases of COVID-19 that require hospitalization nearly 100 percent of the time, health officials said.

Hitting pause was a smart and cautious approach, and continues to be so, especially given that two other alternatives exist, Pfizer and Moderna, to continue mass vaccination programs.

Dozens of health experts met Wednesday to discuss in detail what they know. The continued pause, out of an abundance of caution, is not something to be feared but rather, something on which to build confidence in safety protocols. If the vaccine is pulled off shelves permanently, it will be because of this moment.

* Editorial from The Chicago Tribune


Today's breaking news and more in your inbox

I'm interested in (please check all that apply)


Starting at $4.62/week.

Subscribe Today